Semax is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, designed as a stable, CNS-active analog of the ACTH(4-10) fragment — itself a short segment of adrenocorticotropic hormone known to influence learning and memory in rodent models.

Semax (Met-Glu-His-Phe-Pro-Gly-Pro, or MEHFPGP) strips away the steroidogenic activity of full-length ACTH while amplifying its neurotrophic and neuroprotective properties. It has been approved in Russia for clinical use in stroke management and cognitive impairment, making it one of the few peptides in this class to have crossed the threshold from preclinical research into applied clinical settings. This article reviews the published literature on Semax’s mechanisms and research applications. All content is for educational and research purposes only.

Molecular Profile

Semax’s heptapeptide sequence (MEHFPGP) is built from a core ACTH(4-7) tetrapeptide fragment — the minimal unit retaining cognition-relevant activity — extended at the C-terminus with Pro-Gly-Pro (PGP), a tripeptide that confers enhanced metabolic stability by protecting against exopeptidase degradation. This architecture mirrors the design strategy used for Selank (where tuftsin is extended with PGP), and represents a recurrent approach in Russian neuropeptide pharmacology for creating stable CNS-active compounds.

Crucially, Semax lacks the ACTH motifs responsible for cortisol stimulation (the MC2R-binding domain requires residues beyond the 4-10 window), meaning it does not produce the adrenocortical activation associated with full-length ACTH. Instead, its activity is primarily mediated through interaction with melanocortin receptors (particularly MC4R in the brain) and through direct neurotrophin-regulatory effects.

Key Parameters: – Molecular formula: C₃₇H₅₁N₉O₁₀S – Molecular weight: ~813.93 Da – CAS Number: 80714-61-0 – Primary research administration route: intranasal (in vivo models); both intranasal and IV in clinical settings

ACTH Fragment Pharmacology and Cognitive Research Background

The cognitive effects of short ACTH fragments have been studied since the 1970s, when De Wied and colleagues established that ACTH(4-10) improves avoidance learning in hypophysectomized rats — animals unable to produce endogenous ACTH — demonstrating a CNS-direct action independent of adrenal hormone production. This work established that the 4-10 fragment (and by extension, the 4-7 core) acts centrally through melanocortinergic and monoaminergic pathways rather than via the pituitary-adrenal axis.

Semax builds on this lineage. Research by Varygin and colleagues confirmed that Semax, as an ACTH(4-10) analog with nootropic properties, activates dopaminergic and serotonergic brain systems in rodents — an effect that distinguishes it from GABA-modulatory anxiolytics and positions it closer to monoamine-dependent cognitive enhancement strategies (PMID: 16362768). These monoaminergic effects likely contribute to both its pro-attention and neuroprotective properties.

BDNF Upregulation: A Core Mechanism

The most-cited mechanism underlying Semax’s nootropic and neuroprotective effects is its capacity to rapidly upregulate brain-derived neurotrophic factor (BDNF) and its primary signaling receptor, TrkB. A landmark study by Aldavert-Vera et al. and later by Dolotov and colleagues (PMID: 16996037) demonstrated that a single intranasal application of Semax (50 μg/kg body weight) produced:

• A 1.4-fold increase in BDNF protein levels in the rat hippocampus
• A 1.6-fold increase in TrkB tyrosine phosphorylation (indicating receptor activation)
• A 3-fold increase in BDNF exon III mRNA expression
• A 2-fold increase in TrkB mRNA levels

These changes occurred within hours of administration and represent a meaningful, functionally significant neurotrophin response. BDNF/TrkB signaling is essential for hippocampal long-term potentiation (LTP), the molecular correlate of memory consolidation; its upregulation by Semax provides a direct mechanistic link between the peptide’s administration and improvements in learning and memory observed in behavioral models.

Subsequent research demonstrated that Semax and its component Pro-Gly-Pro fragment activate the transcription of multiple neurotrophins (BDNF, NGF) and their receptor genes following cerebral ischemia, a finding with direct relevance to stroke research (PMID: 19633950).

Neuroprotection Research: Stroke Models

Semax has been most extensively studied in the context of ischemic stroke — both as a neuroprotective agent and as a neurorestorative compound. Ischemic injury triggers a cascade of excitotoxicity, oxidative stress, and neuroinflammation; the window for intervention is narrow and most existing approaches target only one element of this cascade.

Preclinical and early clinical research suggests Semax may address multiple ischemic injury pathways simultaneously. A clinical investigation by Miasoedov et al. examined Semax efficacy across different stages of ischemic stroke rehabilitation (PMID: 29798983), finding that Semax administration — regardless of rehabilitation timing — increased BDNF plasma levels that remained elevated throughout the study period. High BDNF levels were positively correlated with earlier neurological recovery, supporting the clinical relevance of the peptide’s neurotrophin-regulatory mechanism.

An earlier study by Lebedeva et al. performed a combined clinical-electrophysiological evaluation of Semax in acute ischemic stroke, reporting high efficiency and characterizing the immunobiochemical mechanisms underlying its neuroprotective properties (PMID: 10358912). Genome-wide transcriptional analysis further revealed that Semax affects the expression of genes related to immune and vascular systems in rat brain focal ischemia models, with broad effects on cytokine signaling, stress response pathways, and ribosomal protein expression (PMID: 28255762).

Stress Response and Behavioral Research

Beyond acute neuroprotection, Semax has been investigated for its effects on stress-induced behavioral and neurochemical alterations. In a 2021 study by Glazova et al., Semax attenuated behavioral and neurochemical alterations in rats following early-life SSRI exposure — a model of developmental serotonergic disruption — demonstrating that the peptide’s neuroprotective activity extends beyond ischemic contexts to encompass pharmacological stress models (PMID: 33418449).

This broad stress-resilience profile, encompassing both acute neuroprotection (ischemia) and chronic neurochemical stress (developmental toxicity), suggests that Semax research may be relevant to a wide range of neuroscience applications involving neuroplasticity and brain recovery.

Mechanisms Summary

The current evidence supports several convergent mechanisms for Semax’s research-characterized effects:

1. BDNF/TrkB pathway activation: direct upregulation of hippocampal and cortical neurotrophin signaling
2. Monoaminergic system activation: enhanced dopaminergic and serotonergic tone via MC4R-related pathways
3. Neuroinflammation modulation: altered expression of immune-related genes following ischemic challenge
4. Vascular gene regulation: effects on vasodilation and neuroperfusion-relevant gene expression in ischemic tissue
5. Neuroprotective gene expression: induction of pro-survival pathways reducing excitotoxic cell death

Compound Information

• Chemical Name: Semax (L-methionyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-prolyl-glycyl-L-proline)
• Sequence: MEHFPGP
• Molecular Weight: ~813.93 Da
• Classification: Synthetic nootropic neuropeptide; ACTH(4-10) analog
• CAS Number: 80714-61-0
• Research Storage: Lyophilized; stable at −20°C; intranasal delivery (in solution) is the predominant route in animal research models

References

1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. J Neurochem. 2006;99(2):544-553. PMID:16996037
2. Varygin AV, Petrov VI, Dolzhikov AA. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurosci Lett. 2006;393(1):21-25. PMID:16362768
3. Medvinskaya NI, Kolomin TA, Dolotov OV, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Biochemistry (Mosc). 2009;74(6):604-610. PMID:19633950
4. Miasoedov NF, Skvortsova VI, Trofimova LK, Potapova NP. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(5):26-32. PMID:29798983
5. Lebedeva IS, Panikratova YR, Sokolov OY, et al. Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99(4):15-19. PMID:10358912
6. Kolobov VV, Ivanova EO, Shadrina MI, et al. Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats. Mol Biol (Mosk). 2017;51(1):123-133. PMID:28255762
7. Glazova MV, Manchenko DM, Volodina MA, et al. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides. 2021;85:102111. PMID:33418449

Research Use Disclaimer: Semax is sold by Rejuven8 Peptides strictly for in vitro and preclinical research use only. It is not intended for human consumption, veterinary use, or any therapeutic application. This content is educational and does not constitute medical advice. Always comply with applicable laws and institutional guidelines governing peptide research.

All products are sold for research purposes only. Not for human consumption. These statements have not been evaluated by the FDA. This content is for informational and educational purposes only and does not constitute medical advice.